Vemurafenib*
BRAF+ thyroid
BRAF+ adjuvant melanoma
Combo with MEKi
BRAF+ metastatic melanoma
PLX3397
Hodgkin lymphoma
Acute myelogenous lymphoma (AML)
Glioblastoma (GBM)
Prostate
Breast
PLX5622
Alzheimers disease
Multiple sclerosis
Autoimmune & Bone
PLX5622
Rheumatoid arthritis
*Co-development with Hoffmann-La Roche Inc.